Share This Link

Encouraging increased fluid intake might worsen the patient's condition by increasing bladder volume and potentially exacerbating urinary retention due to the anticholinergic effects of the diphenhydramine. This action should be deferred until bladder emptying status has been accurately assessed, as further filling an already distended bladder is detrimental.

While urinary catheterization may be required for severe retention, it is an invasive procedure with risks like urinary tract infection (UTI). It is premature to request this before performing a non-invasive assessment like palpating or scanning the bladder for distension to confirm the need for intervention.

Requesting an intravenous (IV) fluid bolus would be contraindicated if the patient is experiencing urinary retention. Similar to encouraging oral fluids, a bolus would increase circulatory volume and urine production, placing greater strain on a distended bladder and potentially leading to bladder overstretching or rupture if not addressed.

This description relates to the frequency of respiratory infections, not the specific characteristic cough or duration required for a chronic bronchitis diagnosis. While individuals with chronic bronchitis are more susceptible to infections due to impaired mucociliary clearance, the diagnostic criteria are based on the chronic productive cough for a defined duration.

This describes a diagnosis related to tuberculosis, where a tubercle bacillus (Mycobacterium tuberculosis) forms lesions called tubercles, often seen on chest x-ray. Chronic bronchitis is characterized by inflammation and mucus hypersecretion in the bronchi, not by the presence of a tubercle bacillus in the lungs.

Hospitalization for shortness of breath is a general sign of severe respiratory distress from various causes, including severe COPD exacerbation or heart failure. It is not a specific diagnostic criterion for chronic bronchitis, which relies on the historical pattern of a chronic productive cough.

Opioids act as central nervous system depressants by binding to μ-opioid receptors, primarily in the brainstem's respiratory center. This binding inhibits the release of essential neurotransmitters, significantly decreasing the responsiveness of the chemoreceptors to carbon dioxide changes, which is contrary to increased rate and depth. This effect leads to hypoventilation, hypercapnia, and ultimately severe respiratory acidosis, resulting in respiratory failure.

While some opioids can cause minor histamine release, which theoretically could lead to mild bronchoconstriction, the primary and most life-threatening effect is profound central respiratory depression, not peripheral airway narrowing. Bronchoconstriction and wheezing are more characteristic of conditions like asthma or Type I hypersensitivity reactions, not the direct, primary action of opioid agonism on respiratory drive.

Opioids cause hypoventilation by reducing the rate and depth of inhalation, rather than primarily causing an inability to exhale. The issue is a depressed respiratory drive from the brainstem. Exhalation is largely a passive process driven by the elastic recoil of the lungs and chest wall after a reduced or shallow inspiration, making an inability to exhale scientifically inaccurate as the primary effect.

Type I hypersensitivity, or immediate hypersensitivity, is IgE-mediated and typically presents rapidly with symptoms like urticaria (hives), angioedema, bronchospasm, and hypotension due to massive mast cell degranulation and histamine release. While it can cause hypotension, the classic triad of chills, lower back pain, and profound hypotension/tachycardia is not primarily characteristic of this type during a blood transfusion.

Type III hypersensitivity is an immune-complex reaction where soluble antigens and antibodies (IgG or IgM) form complexes that deposit in tissues, often manifesting as vasculitis, arthritis, or nephritis. While it can occur in delayed transfusion reactions, it is not the primary mechanism for the immediate, severe AHTR symptoms described, which are dominated by cell lysis.

Type IV hypersensitivity is a delayed, cell-mediated reaction involving T-lymphocytes and macrophages. It typically takes 24 to 72 hours to manifest and is responsible for contact dermatitis or the tuberculin skin test. The acute, life-threatening symptoms observed within minutes of a transfusion reaction exclude this slower, non-antibody-mediated response.

Immunoglobulin A (IgA) is the predominant antibody found in mucosal secretions like saliva, tears, breast milk, and gastrointestinal fluid, providing local mucosal immunity against ingested or inhaled pathogens. While vital for defense, IgA does not typically trigger the systemic mast cell degranulation and massive mediator release characteristic of anaphylaxis.

Immunoglobulin G (IgG) is the most abundant antibody in plasma, providing long-term humoral immunity and crossing the placenta to confer passive immunity to a fetus. It is a primary mediator of Type II and Type III hypersensitivity reactions. Although it can activate the complement cascade, IgG does not play the principal role in the immediate, IgE-driven pathogenesis of anaphylaxis.

Immunoglobulin M (IgM) is the largest antibody, often existing as a pentamer, and is the first antibody produced during a primary immune response, primarily located in the blood and lymph fluid. It is highly effective at activating the complement system and agglutination but is not the specific key mediator responsible for initiating the rapid mast cell degranulation that defines anaphylaxis.

Active natural immunity is acquired when an individual's own immune system produces antibodies and memory cells in response to direct exposure to a live infectious agent (e.g., recovering from the flu). The example describes the transfer of pre-formed antibodies (IgA) from the mother to the newborn, which does not involve the baby's active production of antibodies.

Active artificial immunity is induced by a medical intervention, such as a vaccination, which exposes the recipient to an attenuated or dead pathogen or its components (antigens) to stimulate the recipient's immune system to actively produce antibodies and memory cells. This differs from the natural, non-medical transfer of maternal antibodies via breast milk.

Passive artificial immunity is conferred by the deliberate injection of pre-formed antibodies (e.g., immune globulin or antitoxin) from an external source into a recipient for immediate, temporary protection or treatment. This is a medical intervention, which is distinct from the biological transfer of antibodies that occurs via the breast milk pathway.

COX-2 selective inhibitors, such as celecoxib, are considered second-generation NSAIDs, developed after the initial non-selective NSAIDs (like aspirin, ibuprofen), which are classified as first-generation. This newer class was designed to minimize the adverse effects, particularly gastrointestinal, associated with the non-selective inhibition of the constitutive COX-1 enzyme.

The primary advantage and design feature of COX-2 selective inhibitors are their reduced risk of gastrointestinal adverse effects, including peptic ulcers, compared to non-selective NSAIDs. Non-selective NSAIDs inhibit COX-1, which produces protective prostaglandins necessary for maintaining the gastric mucosal barrier, making their inhibition the main cause of ulcers.

COX-2 selective inhibitors work by reducing inflammation. The COX-2 enzyme catalyzes the conversion of arachidonic acid into pro-inflammatory prostaglandins. By inhibiting this enzyme, these drugs decrease the synthesis of these inflammatory mediators, thereby lessening the signs and symptoms of inflammation, pain, and fever.

Hypoalbuminemia (normal range 3.5-5.5 g/dL) signifies fewer available binding sites, resulting in a higher fraction of the drug remaining unbound (free) in the plasma. Only the unbound fraction is pharmacologically active and capable of exerting a therapeutic or toxic effect. Therefore, hypoalbuminemia increases the risk of drug toxicity because more active drug is available.

Protein binding acts as a reservoir, slowing the drug's elimination and maintaining a more consistent free drug concentration. While highly protein-bound drugs have a larger fraction sequestered, metabolism is primarily dependent on enzyme activity (e.g., CYP450) and intrinsic clearance, not directly on the initial degree of protein binding.

Only the unbound drug fraction is freely filtered by the glomerulus in the kidneys. High protein binding reduces the amount of free drug available for filtration and subsequent excretion, effectively prolonging the drug's half-life and delaying its elimination from the body, leading to a slower overall excretion rate.